Therapure Biopharma Inc. (Therapure) today announced receipt of a financial contribution from the National Research Council’s Industrial Research Assistance Program (NRC-IRAP). The funding is to support Therapure’s drug delivery program for the treatment of liver cancer and hepatitis C infection.
Therapure’s lead product for infectious disease is a stable protein-drug conjugate of hemoglobin and ribavirin designed to selectively target the delivery of ribavirin to the liver for the treatment of hepatitis C virus (HCV) infection. Therapure’s lead cancer product is a similar conjugate of hemoglobin and floxuridine, which delivers the powerful chemotherapy drug floxuridine directly to the liver as treatment for primary liver cancer. Both products are based on a core expertise in protein chemistry and cell biology that Therapure scientists have pioneered and applied to the natural and highly specific pathway for hemoglobin metabolism as a means of treating chronic and acute liver diseases with high unmet medical need.
Both drug delivery products are in the pre-clinical stage of development. Therapure has recently completed pre-IND and pre-CTA submissions to the US FDA and Health Canada, respectively, as a key step in defining the clinical and regulatory paths for both products and advancing them products to the clinic and the treatment of patients sooner.
In addition to technical and business advisory services, the financial assistance provided by NRC-IRAP will support funding for continued pre-clinical safety and efficacy studies, and bioanalytical method development.
“Therapure is very proud to have been chosen by NRC-IRAP” said Thomas Wellner, President and CEO of Therapure. “This demonstrates the breadth of Therapure’s capabilities in Product and Method Development.”
About Therapure Biopharma Inc.:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market for its clients. Therapure’s Health Canada licensed 130,000 sq. ft. facility, includes manufacturing, research and quality control laboratories and a cGMP warehouse, and is built to U.S. FDA, EMEA, MHRA and Health Canada standards for the aseptic handling and purification of proteins.
For more information, please visit: www.therapurebio.com
Company Contacts:
Thomas Wellner, President and CEO
Therapure Biopharma Inc.
+1 905 286-6204
ceo(at)therapurebio(dot)com
###
Source – http://www.prweb.com/releases/2010/08/prweb4432044.htm
- Pfenex Inc., Through its Reagent Proteins Business Division, Establishes Clinical Supply Agreement With Henry M. Jackson Foundation for the Advancement of Military Medicine
- Crown Biosciences Announces Partnership With Jasco Pharmaceuticals to…
- Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
- Pfenex Inc. announced today that it has entered into a clinical supply agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) to supply cGMP-grade CRM197 carrier protein to support testing and potential development of a conjugate vaccine. Pfenex will supply cGMP-grade CRM197 carrier protein to produce a new conjugate
Crown Bioscience, Inc. announces their partnership with Jasco Pharmaceuticals (Woburn, MA) providing discovery and pre-clinical Cancer Biology services for Jasco’s lead program. Jasco Pharmaceuticals will leverage Crown Bio’s unique models, powerful molecular profiling, and data analysis capabilities providing Jasco Pharma’s high speed medicinal chemistry approach with a synergistic biological complement accelerating the development of Jasco
- Intercell AG (VSE; “ICLL”) and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell’s investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark’s antiviral drug, nitazoxanide, during the first half of 2011. Intercell’s vaccine candidate has demonstrated a sustained reduction of viral load in chronic Hepatitis C (CHC) patients